KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBIT (2016 - 2025)

Historic EBIT for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$862000.0.

  • TherapeuticsMD's EBIT rose 2398.59% to -$862000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 7411.62%. This contributed to the annual value of -$4.8 million for FY2024, which is 4415.11% up from last year.
  • TherapeuticsMD's EBIT amounted to -$862000.0 in Q3 2025, which was up 2398.59% from -$695000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBIT registered a high of $48.4 million during Q4 2022, and its lowest value of -$39.9 million during Q3 2021.
  • Over the past 5 years, TherapeuticsMD's median EBIT value was -$2.5 million (recorded in 2023), while the average stood at -$8.1 million.
  • In the last 5 years, TherapeuticsMD's EBIT soared by 23687.27% in 2022 and then tumbled by 10332.56% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's EBIT stood at -$35.4 million in 2021, then soared by 236.87% to $48.4 million in 2022, then plummeted by 103.33% to -$1.6 million in 2023, then skyrocketed by 143.45% to $700000.0 in 2024, then plummeted by 223.14% to -$862000.0 in 2025.
  • Its EBIT was -$862000.0 in Q3 2025, compared to -$695000.0 in Q2 2025 and -$871000.0 in Q1 2025.